key: cord-1035368-1rircrrk
authors: Anirudhan, Varada; Lee, Hyun; Cheng, Han; Cooper, Laura; Rong, Lijun
title: Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19
date: 2021-02-09
journal: J Med Virol
DOI: 10.1002/jmv.26814
sha: 3eb18ab3f7c0d1f776536be72154f056b2e4e33a
doc_id: 1035368
cord_uid: 1rircrrk

The 21st century has witnessed three outbreaks of coronavirus (CoVs) infections caused by severe acute respiratory syndrome (SARS)‐CoV, Middle East respiratory syndrome (MERS)‐CoV, and SARS‐CoV‐2. Coronavirus disease 2019 (COVID‐19), caused by SARS‐CoV‐2, spreads rapidly and since the discovery of the first COVID‐19 infection in December 2019, has caused 1.2 million deaths worldwide and 226,777 deaths in the United States alone. The high amino acid similarity between SARS‐CoV and SARS‐CoV‐2 viral proteins supports testing therapeutic molecules that were designed to treat SARS infections during the 2003 epidemic. In this review, we provide information on possible COVID‐19 treatment strategies that act via inhibition of the two essential proteins of the virus, 3C‐like protease (3CL(pro)) or papain‐like protease (PL(pro)).

Thus, inhibition of SARS-CoV-2 viral proteases is a promising antiviral strategy. There is a high amino-acid percent homology that exists between the decoded SARS-CoV and SARS-CoV-2 proteases (96% for 3CL pro and 83% for PL pro ). This encourages us to utilize the available information on SARS-CoV proteases to design inhibitors that potentially block activities of the SARS-CoV-2 proteases. Here, we review the characteristics of coronavirus proteases and summarize the promising inhibitory molecules targeting these proteases. We believe this information will aid in designing potential drug candidates to treat the rapidly spreading COVID-19.

The life cycle of SARS-CoV and SARS-CoV-2 begins with their attachment to the host receptor human angiotensin-converting enzyme 2 (hACE2) via the viral surface glycoprotein known as the spike (S) protein. 8 SARS-CoV-2 S protein showed approximately 22-fold tighter binding to hACE2 than SARS-CoV S, which could be one reason why SARS-CoV-2 infection rate is much higher. 9 The Coronaviridae family F I G U R E 1 Classification of coronaviruses and polyproteins of SARS-CoV. (A) Coronavirus classification. The coronavirinae subfamily divides into four genera; alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus. Further division of the betacoronavirus into lineage subgroups is labeled in green. HCoV (human coronavirus), BCoV (bat coronavirus), PEDV (porcine epidemic diarrhea virus), FIPV (feline infectious peritonitis virus), SARS (severe acute respiratory syndrome), and MERS (middle east respiratory syndrome). Seven human coronaviruses are shown in red. (B) Schematics of the SARS-CoV polyproteins with two viral protease cleavage sites. The viral proteases PL pro and 3CL pro cleave the immature polyproteins into 16 nonstructural proteins (labeled 1-16). Pink arrows indicate SARS-CoV PL pro cut sites, whereas green arrows indicate SARS-CoV 3CL pro cleavage sites. The structural proteins include spike (S), envelope (E), membrane (M) and nucleocapsid (N) members have the largest and most complex replicating genomes of all the RNA viruses. The SARS-CoV and SARS-CoV-2 genome is about 29.8 kb long with a 5ʹ cap structure and 3ʹ polyadenylation tract. 10, 11 The replicase gene (rep) is approximately 21 kb long and takes up around 2/3 of the 5ʹ region of the SARS-CoV genome. Following infection, the genomic RNA is released into the cytoplasm, and then two large polyproteins pp1a (~486 kDa) and pp1ab (~790 kDa) are synthesized from two overlapping open reading frames (ORFs) 1a and 1b that encode rep 10 ( Figure 1B) . The SARS-CoV proteases, PL pro and 3CL pro , which undergo auto-catalytic cleavage post translation and aid in co-translational proteolytic processing of these two immature polyproteins to release 16 nonstructural proteins (nsps) named nsp1 through nsp16 that facilitate the formation of the multifunctional membrane-associated replication-transcription complex (RTC). 12 Furthermore, unlike other RNA viruses, SARS-CoV have an exoribonuclease domain (ExoN) in nsp14 that provides proofreading activity that protects the virus from mutagenesis. 13 The structural proteins spike (S), envelope (E), membrane 

The coronavirus 3CL pro enzyme, also known as main protease (M pro ), cleaves the large polyprotein pp1ab at 11 locations, releasing 13 nonstructural proteins. 14 The P1, P2, and P1ʹ positions of the substrate peptide are the major determinants of substrate specificity of SARS-CoV 3CL pro . 7 The P1 position has a well-conserved Glutamine residue and the P2 position has a hydrophobic core. 3CLpro recognizes and cleaves (Leu, Val, Phe, or Met)-Gln ↓ (Ser, Ala, Gly, or Asn) sequences and cleaves the polyproteins into nonstructural proteins Figures 1B and 2A) . While the 3CL pro of other coronaviruses have leucine or isoleucine at position P2, SARS-CoV 3CL pro can have either phenylalanine, valine or methionine at this position. 10, 15 Sequence homology between the cleavage sites of SARS-CoV and SARS-CoV-2 3CL pro is very high, and mismatching residues are highlighted in green in Figure 2A .

The crystal structure of 3CL pro from SARS-CoV is similar to that from other coronaviruses and it comprises of three domains ( Figure 2B ). [16] [17] [18] The chymotrypsin-like structure is constructed from β-barrels contained in the domains I (residues 8-101) and II (102-184); domain III (residues 201-306) contains mostly α-helices.

The active site region is located between domain I and domain II, where amino acid residues Cys145 and His41 form the catalytic dyad of SARS-CoV 3CL pro . 16, 19, 20 Without dimerization, SARS-CoV 3CL pro is inactive and the N-terminal regions of each monomer plays a crucial role in dimer formation. 21 This structural information provides a basis for prototype 3CL pro inhibitors.

The development of novel 3CL pro inhibitors requires proteolytic activity assessment studies of the enzyme. A fluorescence-based assay for peptide cleavage assessment is generally used to characterize the ac- and less than 100 mM NaCl. They also reported drastic differences in kinetic parameters when additional amino acid residues were incorporated in SARS-CoV 3CL pro and suggested the use of the enzyme without any changes to its N-or C-termini. Observed discrepancies between the enzyme kinetic parameters of SARS-CoV 3CL pro reported by other research groups have also been addressed. [22] [23] [24] [25] [26] These variations pose a severe problem in the screening process for inhibitory drugs, and therefore a standard method of enzyme activity assessment that best mimics in vivo conditions are warranted. The use of higher wavelength fluorophore-quencher pair such as Alexa488 and Alexa594 is beneficial to avoid interference from testing compounds. However, Alexa fluorophores are expensive, and hence another 5-FAM and QXL pair (450 nm/520 nm, excitation/emission) was also developed as an effective substrate for high-throughput screening against SARS-CoV 3CL pro enzymatic assays. 27 Despite advancements in the development of 3CL pro enzymatic assays, they are not an alternative for in vitro or in vivo screening in live viral systems in a biosafety level 3 facility. However, they are useful as a necessary tool to screen and characterize potential inhibitors in a nonbiosafety level 3 environment.

Owing to the absolute requirement of coronavirus 3CL pro for viral replication, the protease has been the major focus of antiviral development. An additional factor making this enzyme more appealing as a therapeutic target is that no known human proteases share structural homology and substrate cleavage specificity with SARS-CoV 3CL pro .

Here, we review promising 3CL pro inhibitors that have the potential for treatment of SARS-CoV-2.

In the past, the 3C protease of the closely related human rhinovirus (HRV) has been efficaciously targeted by inhibitors to treat common cold. 28 Rupintrivir (AG7088) developed by Agouron Pharmaceuticals, Inc. is a synthetic compound that selectively and covalently inhibits the 3CL pro of HRV. Rupintrivir showed potent anti-HRV activity in vitro and the drug was formulated into a nasal spray for a doubleblind, placebo-controlled Phase 2 clinical trial in 1999. The drug had minimal side effects and was efficacious in reducing viral titers and symptoms such as nasal discharge. 29 It was later advanced to treat patients with acquired infections in large-scale Phase II/III trails.

However, there was a lack of efficacy in natural infection studies and it was halted for further development.

Rupintrivir was tested against SARS-CoV-2 but showed little enzyme inhibitory activity (IC 50 value of 68 ± 7 µM). 30 This is likely due to the difference in the substrate-binding sites between HRV and SARS-CoV-2. A change in the amide bond between P2 and P3 to a methyleneketone inhibits the drug's ability to bind to the 3CL pro of SARS-CoV-2. 30 However, it might be possible to make modifications to the structure of rupintrivir to enhance its affinity for SARS-CoV-2 which makes it a promising lead compound for further therapeutic development.

Between the viral proteases from SARS-CoV and SARS-CoV-2, Chen et al. 31 found 100% conservation of the sequences involved in the enzymatic reaction, substrate binding and dimer formation. A virtual screen of 7173 purchasable compounds was further conducted to identify possible SARS-CoV-2 3CL pro inhibitors. Two approved hepatitis C virus (HCV) drugs ledipasvir and velpatasvir were reported as suitable candidates based on their modes of action, targets, and lack of side effects (Table 1) Lopinavir has also been shown to block the SARS-CoV 3CL pro , but the study lacked proper randomization and control groups. 34 Lopinavir/ ritonavir was used in a clinical trial to treat COVID-19 patients in China, but it was shown to be ineffective. 35 

The prodrug GC376 is an approved drug for the treatment of feline infectious peritonitis (FIP) which is caused by feline coronavirus (Table 2) . 36 FIP is usually fatal in cats but GC376 has shown promise in the treatment of FIP. 37 Both prodrug GC376 and its parent drug GC373 bind covalently to the catalytic Cys145 of SARS-CoV-2 3CL pro as shown by x-ray crystallography studies. 38 Using the FRET-based assay, it was determined that GC376 blocked proteolytic cleavage activity of MERS 3CL pro with an IC 50 of 1.56 ± 0.09 µM. 39 It was also demonstrated that both parent and prodrug potently blocked SARS-CoV 3CL pro protease activity with an IC 50 value of 0.07 ± 0.02 µM and 0.05 ± 0.01 µM, respectively. Their inhibitory activities against SARS-CoV-2 protease were slightly weaker, with IC 50 values of 0.40 ± 0.05 µM for GC373 and 0.19 ± 0.04 µM for GC376. 38 

The broad-spectrum antiviral ability of certain peptidomimetic α-ketoamides was assessed in Vero E6 cells. 40 Compound 11r was found to be a potent antiviral against SARS-CoV with an EC 50 value of 2.10 μM and against MERS-CoV with an EC 50 value of 5.00 µM. By modifying the chemical structure of 11r, a more stable compound 13a was designed specifically to inhibit SARS-CoV-2 3CL pro . 41 its specificity for the respective 3CL pro enzymes must also be studied.

A Michael acceptor inhibitor named N3 was designed using computeraided drug design to target SARS-and MERS-CoV 3CL pro . 42 N3 could also bind SARS-CoV-2 3CL pro from molecular docking analysis. 43 It was further demonstrated to be an irreversible inhibitor of the protease. In addition, the crystal structure of compound N3 complexed with SARS-CoV-2 3CL pro was solved and N3 was shown to bind to the substrate-binding region which is located between domains I and II. 43 In the HTS of a library of around 10,000 compounds, six compounds presented themselves as possible selective SARS-CoV-2 3CL pro inhibitors: disulfiram, carmofur, ebselen, shikonin, tideglusib, and PX-12. 43 It should be noted that a portion of these hits are promiscuous scaffolds due to the presence of sulfhydryl groups and thus making them not a promising drug lead. However, ebselen covalently bound to 3CL pro but only partially modified Cys145 of the catalytic dyad; therefore it might be a noncovalent inhibitor and a more promising drug lead. Furthermore, ebselen was the strongest inhibitor and had an IC 50 

A previous identified ketone-based SARS-CoV 3CL pro inhibitor, Pfizer compound PF-00835231, was also demonstrated as a potent inhibitor of SARS-CoV-2 3CL pro . 46 indicates that the drug binds to the enzyme via a covalent linkage with the catalytic cysteine residue (PDB:6XHM). 46 The inhibitory potential of PF-00835231 has been confirmed in SARS-CoV-2-infected A549 +ACE2 cells (A549 cells are inherently impermeable to SARS-CoV-2, therefore A549 cells expressing ACE2 receptor exogenously was used). 47 Experiments conducted in vivo wherein PF-00835231 was administered intravenously (IV) to rats, dogs and monkeys indicated that the drug displayed low oral bioavailability (<2%). 49 To decrease the drug clearance and increased the bioavailability of PF-00835231 a phosphate prodrug was designed, PF-07304818, with improved ADME (absorption, distribution, metabolism, and excretion) properties and safety profile. Overall, these data encourage future clinical studies on the prodrug PF-07304818 to treat COVID-19.

In addition to 3CL pro , a papain-like protease (PL pro ) is another at- which are essential for viral replication. 51 It recognizes Leu-Xxx-Gly-Gly ↓ Ala, Lys in the substrates and cleaves between Gly and Ala/Lys residues ( Figure 3A ). Activity profiling of SARS-CoV-2 PL pro revealed that the P2 site has specificity for Gly, the P3 site can tolerate broad amino acid types and the P4 site prefers amino acids with hydrophobic side chains. 52 The SARS-CoV PL pro has four domains and three of them form distinct palm, thumb, and finger domains in addition to a ubiquitinlike N-terminal domain ( Figure 3B ). 51 Apart from its effects on the human innate immunity, cell culture-based studies in human promonocytes provided evidence that SARS-CoV PL pro stimulates tumor growth factor β1 (TGFβ1) synthesis. 59 The elevated levels of TGFβ1 has also been observed in the lungs of SARS-CoV patients and are correlated with the "proinflammatory storm" in the lungs. 58 

A FRET-based assay involving a fluorogenic substrate peptide (similar to that described earlier for SARS-CoV 3CL pro ) has been developed to assess the proteolytic activity of PL pro . 50 Ubiquitin and ISG15-based fluorescence substrates were also frequently used for the PL pro . 60 The (Table 3 ). The structure of GRL0617 complexed with the SARS-CoV-2 PL pro has been solved and revealed that the inhibitor binds in the S3-S4 pockets of the substrate cleft. Binding of the inhibitor causes the closure of the BL2 loop ( Figure 3B ) and narrows the substrate cleft as opposed to the endogenous ligand which enlarges it. This suggests that GRL0617 inhibits the SARS-CoV-2 PL pro by preventing binding of the LXGG motif of the substrate. 60 The structural studies also suggested that a conserved amino acid reside Tyr269 is involved the inhibition of the enzymatic activity by the compound. 11 Indeed, GRL0617 lost its inhibitory activity against the mutated SARS-CoV-2 PL pro in which Tyr269 was replaced by either Thr or Gly. Collectively, these studies strongly encourage further understanding of the therapeutic effects of GRL0617 class of small molecules in mitigating COVID-19. This crystallographic structure can aide in rational drug design, leading to a new generation of naphthalene based PL pro inhibitors.

A yeast-based screening methodology was described by Frieman et al. 66 wherein small molecules that inhibit SARS-CoV multiplication was identified on the basis that unnatural expression of SARS-CoV PL pro in 

Another interesting FDA-approved drug, disulfiram, is capable of blocking enzymatic activities of hepatic alcohol dehydrogenase, methyltransferase, urease, and kinase (Table 1) . 67, 68 Because the cysteine residues of the of PL pro are essential for its enzymatic activities and disulfiram can covalently bind to these residues, Lin et al. 69 

In a structure-based computational screen of small molecules, an antitumor drug Isotretinoin was identified as a potential SARS-CoV-2 PL pro inhibitor based on the predicted enzyme binding affinity (Table 1) . 70 Isotretinoin is a vitamin A derivative which was demonstrated to exhibit strong ACE2 downregulation potential. 71 

Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase

Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes

The life cycle of SARS coronavirus in Vero E6 cells

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

A novel coronavirus associated with severe acute respiratory syndrome

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Characterization of a human coronavirus (strain 229E) 3C-like proteinase activity

Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Mechanism of the maturation process of SARS-CoV 3CL protease

Conservation of substrate specificities among coronavirus main proteases

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS

Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery

Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3'-digallate (TF3). Evid Based Complement Alternat Med

The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain

The substrate specificity of SARS coronavirus 3C-like proteinase

Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus

The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

of Lopinavir-ritonavir in adults hospitalized with severe COVID-19

Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor

Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structurebased design, synthesis, and activity assessment

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Structure of main protease from human coronavirus NL63: insights for wide spectrum anticoronavirus drug design

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing

Safety and efficacy of Ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial

The Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

Comparative study of a 3CL (pro) inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme

Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design

A noncovalent class of papainlike protease/deubiquitinase inhibitors blocks SARS virus replication

Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63

Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition

Expression of elevated levels of proinflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling

Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome

Correlation between TGF-beta1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease

Crystal structure of SARS-CoV-2 papainlike protease

Deubiquitinating activity of the SARS-CoV papain-like protease

Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease

Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation

X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

Yeast based small molecule screen for inhibitors of SARS-CoV

In vivo inhibition of aldehyde dehydrogenase by disulfiram

Inhibition of urease by disulfiram, an FDA-approved thiol reagent used in humans

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Systematic cell line-based identification of drugs modifying ACE2 expression

The authors declare that there are no conflict of interests.

Drafting of the manuscript: Varada Anirudhan and Laura Cooper. 

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

https://orcid.org/0000-0003-2570-8120Laura Cooper https://orcid.org/0000-0002-6322-1260